Based on our findings, in advanced lung adenocarcinoma patients having insufficient tissue samples for EGFR mutation testing, liquid biopsy to determine EGFR mutation status might be particularly useful if they have lymph node involvement and/or bone metastasis. This evidence concerns the gene EGFR and lung adenocarcinoma.